uniQure's Huntington's Bet: Real Catalyst, Priced Like a Sure Thing

# uniQure's Huntington's Bet: Real Catalyst, Priced Like a Sure Thing

Let's start with the number that should stop you mid-scroll: uniQure is up roughly five-fold from its 52-week low of $8.73, and more than doubled in the last 90 days alone. That's not a meme stock discovering Reddit. That's a company that got a genuine regulatory reprieve from the FDA and watched the market re-rate it accordingly. The question now isn't whether the catalyst was real — it was — but whether the stock has quietly sprinted past the news.

The Setup: A Reversal Nobody Saw Coming

Back on June 17, the FDA did something it rarely does: it reopened a door it had slammed shut. uniQure's gene therapy for Huntington's disease, AMT-130, had been stuck in regulatory purgatory since late 2025, when the agency expressed skepticism about the company's reliance on external control data. Then, seemingly out of nowhere, the FDA reversed course and cleared a path for a Biologics License Application filing. Shares ripped 78% in a single session. The Wall Street Journal ran the headline; H.C. Wainwright reiterated its Buy rating a week later. This wasn't hype — it was a legitimate de-risking event for a company that, for a hot minute, looked like it might never get its lead asset across the regulatory finish line.

Since then, the stock has just kept grinding. A 3.3% pop in mid-August. A ~7.6% surge days before this writing. Momentum on momentum, all nominally in service of the same thesis: AMT-130 is heading toward a Q3 2026 BLA filing, and the FDA — for now — seems willing to let it through the door.

Where the Story Gets Interesting

Here's the part that should make you pause before chasing this thing further. The FDA has already flip-flopped on this program once. Skepticism, then acceptance, all within about six months. That's not exactly a foundation of granite. If the agency's concerns about external control data were "resolved," great — but if they were merely accommodated procedurally rather than substantively addressed, that same skepticism could resurface the moment the actual BLA lands on a reviewer's desk. And with the Q3 filing window closing out in the next month, that reckoning is close.

Meanwhile, the fundamentals haven't budged much. Q2 2026 revenue came in at $5.8 million — up 11%, sure, but still a rounding error, almost entirely licensing income. Net income sits at -$81 million for the quarter. Gross margins are negative 1,350%. This is a company burning cash (-$77.6 million in operating cash flow last quarter) with $552 million in debt against a debt-to-equity ratio north of 170. The saving grace is a fat cash pile — reportedly enough runway into 2029 — so dilution isn't an immediate threat. But make no mistake: this is a binary, pipeline-dependent story wearing the clothes of a momentum stock.

And then there's the tell that always makes me raise an eyebrow: CEO Matthew Kapusta has been selling stock — three separate sales totaling roughly $953,000 — right into this rally. Insiders selling into strength isn't automatically damning, but it's not exactly a vote of confidence in more upside from here either.

Where the Street Sits

Analysts are genuinely split, which tells you something. Wells Fargo has a $75 target. Wolfe Research says $65. Barclays trimmed to $60. Our own base case lands at $46.35, with a bear case of $37.34 if the filing stumbles and a bull case of $70.21 if everything clicks. RSI is sitting around 60, short interest is a non-trivial 16.6% of float, and the stock is trading well above the $43–45 support zone that would flag a momentum breakdown.

The Bottom Line

This is a real catalyst stock, not a fake one — that distinction matters and it's why the rally has legs beyond pure speculation. But "real catalyst" and "correctly priced" are two different animals. At current levels, the market isn't just betting the BLA gets filed on schedule — it's betting the FDA's newfound goodwill survives contact with the actual paperwork. Given this agency's track record on this exact program, that's a bet I'd want to make with my eyes open, not my eyes closed. The next four to six weeks decide whether this was a well-earned re-rating or a very expensive lesson in regulatory whiplash.